michigan glp-1 stomach paralysis lawsuit Ozempic for Gastroparesis GLP-1 Drug Lawsuits

Biochem J 390:455464

GLP-1 receptor agonists effect on cognitive function in diabetes: a systematicreview / metaanalysis

Blue Cross began covering Saxenda in 2015 when federal regulators approved it to treat weight loss, adding coverage of Wegovy in 2021 and Zepbound in 2023

LifeMD is a 73% equity holder in WorkSimpli, a SaaS document management program that has over 170,000 subscribers with high-margin recurring revenue with the potential for a $100 million exit in 2024

These lawsuits may also increase legislators attention and focus on Californias CPOM (and related) laws

Twenty-four hours EE was slightly but statistically significantly reduced with liraglutide treatment (both 1.8 and 3.0 mg), partly explained by a treatment-related reduction in body weight over the 5-week period